BlueSphere Bio's CSO Alan Korman Receives Prestigious 2025 William B. Coley Award in Immunology
Alan Korman Honored with the 2025 William B. Coley Award
In a significant recognition for groundbreaking research in cancer therapies, Alan Korman, Chief Scientific Officer of BlueSphere Bio, is named the recipient of the 2025 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. The award, presented by the Cancer Research Institute (CRI), celebrates his essential role in developing immunotherapies, particularly immune checkpoint inhibitors like ipilimumab and nivolumab.
A Legacy in Cancer Research
Korman's work has fundamentally transformed the treatment landscape for various cancers, especially for metastatic melanoma patients. His contributions have been instrumental in not only advancing the field of immuno-oncology but also providing lifesaving therapy options to patients across the globe.
“This award is a testament to Alan's exceptional career and his groundbreaking discoveries,” stated Keir Loiacono, Chief Executive Officer of BlueSphere Bio.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.